Coport L 25/5 

Presentation: Each tablet of Coport L 25/5 contains Empagliflozin 25 mg and Linagliptin 5 mg.

Indications: Coport L is indicated in adults with type 2 diabetes mellitus to improve glycemic control when treatment with both empagliflozin and linagliptin is appropriate.

Dosage and Administration: The recommended dose is one tablet once daily in the morning, with or without food. The specific strength (e.g., 10/5 mg or 25/5 mg) will be determined by the physician based on individual needs. Assess renal function before initiating.

Side Effects: Common side effects may include increased urination, urinary tract infections, and genital fungal infections. Hypoglycemia may occur when used with insulin or sulfonylureas. Other possible side effects include nasopharyngitis.

Precautions: Contraindicated in severe renal impairment, end-stage renal disease, dialysis, and hypersensitivity to empagliflozin or linagliptin. Not recommended during the second and third trimesters of pregnancy. Use with caution in patients with renal impairment, low blood pressure, heart failure risk, and those on diuretics. Monitor for signs of pancreatitis, ketoacidosis, and Fournier's gangrene.

Storage: Store below 30°C, away from light and moisture. Keep out of reach of children.

Important Note: This information is for general knowledge only, not medical advice. Consult your doctor/pharmacist for specific guidance. They know your condition best.